Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have been given an average rating of “Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $3.75.
Separately, Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Saturday, August 11th.
Shares of SNSS traded up $0.04 during midday trading on Friday, hitting $0.46. 1,069,010 shares of the stock were exchanged, compared to its average volume of 285,431. Sunesis Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $7.69. The firm has a market cap of $15.80 million, a P/E ratio of -0.32 and a beta of 2.02.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04. Research analysts expect that Sunesis Pharmaceuticals will post -0.82 earnings per share for the current year.
A hedge fund recently raised its stake in Sunesis Pharmaceuticals stock. Millennium Management LLC lifted its stake in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 594.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 106,599 shares of the biopharmaceutical company’s stock after purchasing an additional 91,248 shares during the period. Millennium Management LLC owned about 0.31% of Sunesis Pharmaceuticals worth $290,000 at the end of the most recent quarter. 44.15% of the stock is owned by institutional investors.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Read More: What is the NASDAQ?
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.